

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

GENOME AND COMPANY,
Petitioner,

v.

THE UNIVERSITY OF CHICAGO,
Patent Owner.

Case PGR2019-XX
U.S. Patent No. 9,855,302 B2

**DECLARATION OF JONATHAN BRAUN, M.D., Ph.D., IN SUPPORT OF
PETITION FOR *POST GRANT* REVIEW OF U.S. PATENT NO. 9,855,302**

TABLE OF CONTENTS

	Page(s)
I. INTRODUCTION	1
II. BACKGROUND AND QUALIFICATIONS	2
III. APPLICABLE LEGAL PRINCIPLES	5
A. Burden of Proof	5
B. Prior Art	5
C. Obviousness	6
D. Enablement Requirement	10
IV. PERSON OF ORDINARY SKILL IN THE ART	12
V. THE '302 PATENT	13
A. Summary Of The '302 Patent	13
B. The Only Data In The '302 Patent Is Mouse Data	25
C. Prosecution Of The '302 Patent And A Continuing Application of the '302 Patent	27
1. Prosecution of US Patent Application 15/170,284 Which Issued As The '302 Patent	27
D. Prosecution of Child US Patent Application 15/718,735	33
E. Claim Construction for the Claims of the '302 Patent	38
VI. STATE OF THE ART AT THE TIME OF THE CLAIMED INVENTION	39
A. It Was Known At The Tme Of The Invention That Cancer Is A Term Covering A Variety Of Specific Diseases With Disparate Etiologies, Outcomes, And Therapies And that Cancer Treatment Is Highly Unpredictable	39
B. It Was Known At The Time Of The Invention That Immune Checkpoint Inhibitors Work Only On A Subset Of Cancers And Are Highly Unpredictable	44
C. It Was Known At The Time Of The Invention That Gut Microbiota Influence Health And The Immune System In Unpredictable Ways	46
D. It Was Known At The Time Of The Invention That Some Species and Strains of <i>Bifidobacterium</i> Had Anti-Tumor Activity.	49

VII. THE CLAIMS OF THE ‘302 PATENT ARE INVALID	52
A. Claims 1-29 Are Invalid For Failing To Meet The Enablement Requirement Under §112(a)	52
1. The Nature of the Invention – Treating Cancer In A Human Subject	53
2. The Level of Ordinary Skill in the Art Is High	54
3. The Claims Are Extremely Broad - Treating All Cancers With All Immune Checkpoint Inhibitors and All Species of <i>Bifidobacterium</i>	55
4. The Working Examples Are Limited To a Few Mouse Experiments Involving Two Types of Cancer, A Single Immune Checkpoint Inhibitor, And A Few Species of <i>Bifidobacterium</i>	58
5. The ‘302 Patent Provides Nearly No Guidance	59
6. Cancer Treatment Employing Immune Checkpoint Inhibitors and <i>Bifidobacterium</i> Is Highly Unpredictable	60
7. Extensive and Undue Experimentation Is Required To Practice The Full Scope of the Claimed Invention	62
VIII. CLAIMS 1-29 OF THE ‘302 PATENT ARE OBVIOUS	66
A. Korman ‘401 In View Of Singh And Dong Render Obvious Claims 1-9, 12-17, and 19-25, and 27-28.....	66
B. Korman ‘401 In View Of Singh And Dong And Further In View Of Van Der Waaij Renders Obvious Claims 10, 11 And 26.....	68
C. Korman ‘401 In View Of Singh And Dong And Further In View Of Topalian Renders Obvious Claims 18 And 29	69
D. Korman ‘401 In View Of Kohwi Render Obvious Claims 1-4, 7-9, 12-17, 19-25, And 27-28.....	80
E. Korman ‘401 In View Of Kohwi And Further In View Of Singh Render Obvious Claims 5-6 And 23-24.....	83
F. Korman ‘401 In View Of Kohwi And Further In View Of Van Der Waaij Renders Obvious Claims 10, 11 And 26	83
G. Korman ‘401 In View Of Kohwi And Further In View Of Topalian Render Obvious Claims 18 And 29	84
A. Korman ‘401 In View Of Mohania And Prakash ‘449 Render Obvious Claims 1-9, 12-17, And 19-25, And 27-28.....	95
B. Korman ‘401 In View Of Mohania And Prakash ‘449 And Further In View Of Van Der Waaij Renders Obvious Claims 10, 11 And 26.....	98

C. Korman ‘401 In View Of Mohania And Prakash And Further In View Of Topalian Renders Obvious Claims 18 And 29.....99

IX. CONCLUSION.....111

I, Jonathan Braun, M.D., Ph.D., being of legal age, hereby declare affirm, and state the following:

I. INTRODUCTION

1. I have been retained on behalf of Genome & Company/Petitioner, to serve as an independent expert and provide expert opinions regarding U.S. Patent No. 9,855,302 (“the ‘302 patent”) (Ex. 1001). I have personal knowledge of the facts and opinions set forth in this declaration, and, if called upon to do so, I would testify competently thereto. All of the opinions and conclusions found in this declaration are my own.

2. I have been informed that Genome & Company is petitioning the Patent Trial and Appeal Board (“PTAB”) to institute a post-grant review of the ‘302 patent and requests that the PTAB cancel all of the claims of the ‘302 patent on the basis that the claims are not enabled and the claims are obvious.

3. I have been asked to consider and provide my opinions regarding the ‘302 patent claims, including the technical subject matter of the ‘302 patent and the application of various references that are prior art to the ‘302 patent. In particular, I have been asked to consider what a person of ordinary skill in the art would have understood from the ‘302 patent, whether the specification teaches a person of ordinary skill in the art how to make and use the claimed invention without undue

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.